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ABSTRACT 
Aims/hypothesis 
Validated biomarkers are needed to monitor the effects of immune intervention in 
individuals with type 1 diabetes. Despite their importance, few options exist for monitoring 
antigen-specific T cells. Previous reports described a combinatorial approach that enables 
the simultaneous detection and quantification of multiple islet-specific CD8+ T cell 
populations. Here, we set out to evaluate the performance of a combinatorial HLA-A2 
multimer assay in a multi-centre setting. 
 
Methods 
The combinatorial HLA-A2 multimer assay was applied in five participating centres using 
centralised reagents and blinded replicate samples. In preliminary experiments, samples 
from healthy donors were analysed using recall antigen multimers. In subsequent 
experiments, samples from healthy donors and individuals with type 1 diabetes were 
analysed using beta cell antigen and recall antigen multimers. 
 
Results 
The combinatorial assay was successfully implemented in each participating centre, with 
CVs between replicate samples that indicated good reproducibility for viral epitopes (mean 
%CV = 33.8). For beta cell epitopes, the assay was very effective in a single-centre setting 
(mean %CV = 18.4), but showed sixfold greater variability across multi-centre replicates 
(mean %CV = 119). In general, beta cell antigen-specific CD8+ T cells were detected more 
commonly in individuals with type 1 diabetes than in healthy donors. Furthermore, CD8+ T 
cells recognising HLA-A2-restricted insulin and glutamate decarboxylase epitopes were 
found to occur at higher frequencies in individuals with type 1 diabetes than in healthy 
donors. 
 
Conclusions/interpretation 
Our results suggest that, although combinatorial multimer assays are challenging, they can 
be implemented in multiple laboratories, providing relevant T cell frequency measurements. 
Assay reproducibility was notably higher in the single-centre setting, suggesting that 
biomarker analysis of clinical trial samples would be most successful when assays are 
performed in a single laboratory. Technical improvements, including further standardisation 
of cytometry platforms, will likely be necessary to reduce assay variability in the multi-
centre setting. 
 
 
INTRODUCTION 
Effective biomarkers are needed to monitor autoimmune progression in individuals at risk of 
developing type 1 diabetes mellitus and to monitor interventions in those with established 
disease [1]. This need is particularly compelling in light of the increasing number of clinical 
trials designed to test the efficacy of therapies to halt autoimmune destruction of pancreatic 
beta cells [2]. However, there is a dearth of reproducible assays that can be applied to frozen 
peripheral blood mononuclear cells (PBMCs). For successful trials, surrogate biomarkers 
may enable the identification of immune profiles associated with favourable outcomes, 
allowing stratification of subgroups based on predicted response to therapy. Immune 
biomarkers are equally important for mechanistic explorations in the context of trials that 
failed to achieve significant clinical outcomes. Such biomarkers may help to differentiate 
between lack of biological effect and immune modifications that did not translate into 
clinical benefit, thereby informing the design of subsequent trials [3]. 
 
Assays that measure the frequencies of beta cell-reactive CD8+ T cells provide attractive 
options for the detection of candidate biomarkers. Such autoreactive CD8+ T cells have been 
identified in pancreatic biopsies from people with newly diagnosed and long-term diabetes 
[4]. Furthermore, CD8+ T cells are the most abundant lymphocyte population in insulitic 
lesions [5] and occur in the pancreatic transplants of recipients with recurrent autoimmune 
disease [6]. Preproinsulin (PPI)-reactive CD8+ T cells have also been shown to kill beta cells in 
vitro [7]. In addition, non-obese diabetic mice lacking expression of MHC class I molecules 
are resistant to diabetes [8], whereas adoptive transfer of CD8+ T cells causes disease in 
recipient mice [9, 10, 11]. These observations suggest a pathogenic role for CD8+ T cells in the 
autoimmune process, consistent with the identification of multiple HLA class I alleles as risk 
variants for the development of diabetes [12, 13]. 
 
Although other assay formats are available, HLA class I multimer staining is an attractive 
option that allows direct ex vivo detection of autoreactive CD8+ T cells using relatively small 
numbers of PBMCs [14]. Previous studies have validated this method and demonstrated clear 
visualisation of CD8+ T cells specific for recall antigens [15]. In contrast, self-antigen-specific 
CD8+ T cells typically display lower avidities and tend to stain less distinctly with HLA class I 
multimers [16]. Combinatorial staining solves these problems by assigning a pair of 
fluorochromes to each epitope specificity [17]. Such dual staining more readily separates 
background from multimer-specific signals, allowing efficient interrogation of multiple 
specificities within a single assay tube. Consequently, this approach has been advanced to 
monitor immune responses in various settings [17, 18] and further extended on a mass 
cytometry platform to interrogate a vast number of specificities [19]. 
 
Using this strategy, autoreactive CD8+ T cells have been detected in frozen samples from 
individuals with type 1 diabetes, first-degree relatives, healthy donors and islet cell-
transplant recipients [1]. However, it remains unclear whether this assay can be 
implemented reliably across different laboratories. We therefore sought to test the 
potential utility of combinatorial HLA class I multimer staining by assessing reproducibility in 
a single centre vs multiple centres. To aid visualisation, we modified the staining protocol to 
include the tyrosine kinase inhibitor dasatinib, which helps stabilise T cell receptor 
expression to maximise the uptake of HLA class I multimers [20]. 
 
 
METHODS 
Human samples 
Three sets of frozen HLA-A*02:01+ (designated HLA-A2+ hereafter) samples were obtained 
with informed consent within approved studies coordinated by the Benaroya Research 
IŶstitute ;B‘IͿ. Saŵple set ϭ ĐoŶsisted of repliĐate ǀials of ϱ × 106 PBMCs from five healthy 
donors obtained through the BRI Control Repository. Sample set 2 consisted of replicate 
ǀials of ϭϬ × 106 PBMCs from five iŶdiǀiduals ǁith tǇpe ϭ diaďetes ;ŵeaŶ age Ϯϱ ± 5.6 years; 
40% female; disease duration 1.7 to 6.6 years; all insulin treated) obtained through the BRI 
Diaďetes ‘epositorǇ. Saŵple set ϯ ĐoŶsisted of repliĐate ǀials of ϭϬ × 106 PBMCs from ten 
healthy donors ;ŵeaŶ age ϯϲ ± 12 years; 60% female; all screened to exclude autoantibody-
positive individuals and first-degree relatives of autoimmune individuals) obtained through 
the B‘I aŶd ŶiŶe iŶdiǀiduals ǁith tǇpe ϭ diaďetes ;ŵeaŶ age ϯϬ ± 9.6 years; 33% female; 
disease duration <5 years; all insulin treated) obtained through the BRI Diabetes Repository, 
together with a spiked sample prepared by mixing a cytomegalovirus (CMV)-specific T cell 
clone (2F3) and a PPI-specific T cell clone (2D5; both clones obtained froŵ KiŶg͛s College 
London, London, UK) with PBMCs from an HLA-A2− donor at frequencies of approximately 
0.55% and 0.38%, respectively. All sample vials were transferred between centres using a 
liquid nitrogen dry shipper. Characteristics of the individuals who provided samples are 
summarised in ESM Tables 1, 2 and 3. 
 
Peptides and HLA class I multimers 
Peptides representing immunodominant beta cell and recall epitopes (Table 1) were 
synthesised by Genscript (Piscataway, NJ, USA). HLA-A2 monomers were obtained through 
the National Institutes of Health (NIH) Tetramer Core Facility (Atlanta, GA, USA) and 
distributed to participating centres together with Qdot-labelled streptavidins and 
antibodies. Qdot multimers were prepared essentially as described previously [14]. Briefly, 
20 μl of eaĐh ŵoŶoŵer ;Ϭ.ϭ μg/μl) in PBS was multimerised by adding 2.2 μl of the 
appropriate Qdot-labelled streptavidin (Thermo Fisher Scientific, Waltham, MA, USA) for 
30 min at 4°C. D-biotin (final concentration 25 μŵol/l; AǀiditǇ, Aurora, CO, USAͿ ǁas 
subsequently added for 20 min at 4°C, followed by 1 μl of ϭϮ.ϱ% ;ǁt/ǀol.Ϳ BSA/PBS solutioŶ. 
Multimers were stored at 4°C and used within 2 weeks. 
 
Thawing and viability assessment of PBMC samples 
PBMCs were handled according to Immunology of Diabetes Society T Cell Workshop 
recommendations [21, 22]. Briefly, heparinised blood was fractionated by Ficoll underlay, and 
PBMCs ǁere frozeŶ graduallǇ at a ĐoŶĐeŶtratioŶ of ϭ × 107/ml in fetal bovine serum 
supplemented with 10% dimethyl sulfoxide. After storage and shipment, cryovials were 
transferred to a 37°C water bath, agitated until the cells were just thawed, and topped up 
with 1 ŵl ŵediuŵ ;IsĐoǀe͛s Modified DulďeĐĐo͛s Mediuŵ or ‘PMI + ϱϬ% [ǀol./ǀol.] fetal Đalf 
serum). Cells were then transferred to a 15 ml sterile tube prefilled with 1 ml medium, 
washed, pelleted, rested for 15 min, assessed for viability using Trypan Blue and re-
suspeŶded after a fiŶal ǁash at ϮϬ × 106 cells/ml in PBA buffer (PBS + 0.5% [wt/vol.] BSA + 
0.01% [wt/vol.] sodium azide). Samples with viability and recovery counts >50% were 
considered acceptable and used for multimer staining. 
 
Combinatorial multimer staining 
Combinatorial staining was performed on all recovered cells essentially as described 
previously [14]. In addition, cells were treated for 15 min at 37°C with 50 nmol/l dasatinib 
prior to assay. Batches of five samples were processed in parallel. For each batch, a Qdot 
master mix was prepared by combining 5 μl of eaĐh Qdot-labelled multimer (summarised in 
Table 1) with 200 μl PBA. EaĐh saŵple ǁas pelleted, re-suspended in 57 μl Qdot ŵaster ŵiǆ 
and incubated for 15 min at 37°C. Cells were then stained for 30 min at 4°C with: 1.5 μl aŶti-
CD8 allophycocyanin (BD Biosciences, San Jose, CA, USA), 2.5 μl eaĐh of aŶti-CD4/CD14/ 
CD16/CD20/CD40-FITC (dump channel; eBioscience, Waltham, MA, USA), and 3 μl ϳ-
aminoactinomycin D (7-AAD). Single-colour compensation controls were generated using 
cells disrupted with 1% Tween 20 (for the 7-AAD control) and BD CompBeads coated either 
with one of the directly conjugated antibodies or with a biotin-conjugated anti-CD8 
antibody followed by one of the relevant streptavidins. After staining, cells were washed 
and acquired by flow cytometry, with the equipment configurations detailed in ESM Table 4. 
Each cytometer was optimised daily using CS&T research beads (BD Biosciences). Data were 
analysed centrally (in a sample-blinded fashion) in Seattle using a Boolean gating strategy [14] 
(summarised in ESM Figure 1) to enumerate viable dump-negative CD8+ singlets that were 
uniquely positive for each pair of Qdot labels. A 0.05% cut-off for positive responses was 
chosen based on the level of staining observed for the non-interfacing control multimer 
(mean ±3 SDs). Each centre also analysed their own data in a blinded fashion, setting 
thresholds for positive staining using their own specific cut-offs, again with reference to the 
non-interfacing multimer together with qualitative criteria such as the distribution pattern 
of staining (i.e. clustering vs spread). In both analyses, blind calls were made by classifying 
an individual with positive staining for at least one beta cell antigen multimer as an 
individual with type 1 diabetes, and an individual without positive staining for beta cell 
antigen multimers as a healthy donor. 
Statistical methods 
Systematic variations between centres were evaluated using one-way ANOVA (with centres 
as columns and matched observations in each row). Where p values were <0.05, column 
ŵeaŶs ǁere Đoŵpared usiŶg TukeǇ͛s ŵultiple ĐoŵparisoŶs test. AgreeŵeŶt ďetǁeeŶ 
replicate samples (assayed either in a single centre or between centres) was assessed using 
%CV, calculated as the ratio of the SD and mean × 100. Aggregated multimer data were 
arranged as a contingency table, and the association of positive responses in samples from 
individuals with type 1 diabetes vs healthy donors was evaluated using the Fisher exact test. 
Contingency analysis was performed using the VassarStats online contingency table 
resource. All other statistical analyses were carried out using Prism version 6.01 (GraphPad 
Software, La Jolla, CA, USA). 
 
Viability and cell recovery for shipped PBMC samples 
Replicate cryovials from healthy donors (sample set 1) for analysis with recall antigen 
multimers (ESM Table 1) and replicate cryovials from healthy donors and individuals with 
type 1 diabetes (sample set 3) for analysis with beta cell and recall antigen multimers (ESM 
Table 3) were thawed at each participating centre and assessed for viability (Figure 1). For 
sample set 1, no differences in recovery were observed among centres (median 64.0%; 
range 52.5–65.6%), and differences in viability were modest (median 91.5%; range 86.4–
95.0%), potentially reflecting a systematic counting bias across centres. For sample set 3, 
significantly lower viability and recovery rates were obtained in Denver, possibly because 
the samples were stored for longer before analysis. Despite these differences, each vial 
provided sufficient material for analysis. 
 
Reproducibility of multimer analysis of recall antigen-reactive CD8+ T cells 
To implement the combinatorial assay in each centre, five samples from HLA-A2+ healthy 
donors (sample set 1) were distributed as identical replicate vials and assessed qualitatively 
and quantitatively for responses to CMV, Epstein–Barr virus (EBV) and influenza epitopes. 
All samples were pre-treated with dasatinib and stained using multimer panel 1 (listed in 
Table 1). Representative data are shown in Figure 2a. Although some numerical differences 
were observed (Figure 2b), the staining results were statistically equivalent among centres 
for all three viral epitopes, with acceptable %CVs (mean 33.8; SD 12.5) for specificities above 
the positive threshold of 0.05%. The panel was designed to include five different Qdots (585, 
605, 655, 705 and 800) to verify that each centre was able to detect signals in each channel 
despite the use of different cytometer configurations (ESM Table 4). This sample set also 
included an HLA-A2−control sample, for which the numbers of positive events detected with 
recall antigen multimers were consistently lower than or equivalent to those detected with 
the non-interfacing control multimer in all channels. 
 
Single-centre reproducibility of multimer analysis of beta cell antigen-reactive CD8+ T 
cells 
To validate the detection of beta cell antigen-specific CD8+ T cells, we first evaluated assay 
reproducibility in a single laboratory (Seattle) by staining three identical replicate vials from 
five HLA-A2+ individuals with type 1 diabetes (sample set 2). Each blind-coded sample was 
thawed, pre-treated with dasatinib, stained using multimer panel 2 (listed in Table 1) and 
analysed before unblinding. As summarised in Table 2, the assay exhibited good agreement 
between replicate samples based on the observed %CVs. The mean %CV across specificities 
for beta cell antigen multimers was 18.4. As expected, assay precision was better for viral 
specificities, with a mean %CV of 6.2. For replicate beta cell epitope-specific frequency 
measurements, SDs were consistent, ranging from 0.005 to 0.010. As a consequence, %CV 
values were highest for those specificities with the lowest frequencies in the sample set, 
such as islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), which 
yielded a mean %CV of 45.1. 
 
Multi-centre reproducibility of multimer analysis of beta cell antigen-reactive CD8+ T 
cells 
To evaluate assay reproducibility across multiple centres, nine samples from HLA-
A2+individuals with type 1 diabetes, ten samples from HLA-A2+ healthy donors and a clone-
spiked sample (sample set 3) were distributed as identical replicate vials in a blinded 
fashion, pre-treated with dasatinib and stained using multimer panel 2 (listed in Table 1). 
Staining results for the spiked control and a representative sample are shown in Figure 3a,b, 
respectively. For the spiked control sample, each centre observed positive staining (>0.1% of 
total CD8+ T cells) for the CMV- and PPI-specific clones (Figure 3c) at percentages close to 
the theoretical spiked values (0.58% for CMV and 0.34% for PPI vs theoretical values of 
0.55% and 0.38%, respectively). 
 
Multimer staining results for each individual sample across all participating centres are 
shown in Fig. 4. Across all centres, background staining was typically low (with an overall 
mean of 0.0082% and an SD of 0.01% across all samples), and high positive results tended to 
be more consistent. To assess the technical reproducibility of the assay, we calculated %CVs 
across all multi-centre replicates for each multimer specificity (Table 3). The overall mean 
%CV was 119 for beta cell antigen multimers. As such, the multi-centre beta cell antigen 
data were 3.5-fold more dispersed than the multi-centre recall antigen data and 
approximately sixfold more dispersed than the single-centre beta cell antigen data. For 
replicate beta cell epitope-specific frequency measurements, SDs for the multi-centre data 
were also higher compared with the single-centre data, ranging from 0.007 to 0.11. %CV 
values were highest for the PPI epitope, which also had the highest SD, and lowest for the 
GAD and insulin B epitopes. The decreased precision of the multi-centre data is illustrative 
of the technical challenges associated with implementing a complex multi-parameter flow 
assay to perform rare-event analysis using non-identical cytometer configurations. 
 
To further evaluate assay reproducibility across multiple centres, we analysed the data using 
one-way ANOVA. Systematic variation was not evident for the viral recall antigens or for the 
beta cell antigens GAD, islet antigen-2 (IA-2), IGRP or islet amyloid polypeptide (IAPP) 
(Figure 5). However, significant differences were detected for the insulin B and PPI epitopes 
(Figure 6). Specifically, higher frequencies of insulin B-specific CD8+ T cells were detected in 
Paris compared with Seattle or Leiden, and higher frequencies of PPI-specific CD8+ T cells 
were detected in Denver compared with all other participating centres. Equivalent 
differences were not observed for the spiked control sample. As the insulin B and PPI 
multimer staining data also had the highest SDs, it is likely that systematic error or technical 
issues contributed to the observed differences between centres. 
 
Central calls were made for each sample before unblinding to assign individuals as having 
type 1 diabetes or healthy donor based on the presence or absence of multimer-positive 
populations (>0.05% of viable CD8+ T cells). As summarised in Table 4, these qualitative calls 
were moderately accurate, with average sensitivity of 68% and specificity of 76% (SDs were 
11% and 10%, respectively). The same analysis was repeated in each individual centre 
(Table 5), but these qualitative calls were less favourable, with average sensitivity of 64% 
and specificity of 65% (SDs were 16% and 13%, respectively). 
 
Aggregated analysis of beta cell antigen-reactive CD8+ T cells 
To evaluate assay results in the context of disease status, multimer staining data from all 
centres were aggregated (barring data from the spiked sample and PPI-specific frequency 
measurements from Denver), and pairwise comparisons were performed between 
individuals with type 1 diabetes and healthy donors. The magnitude of staining with the 
insulin B and GAD multimers was significantly higher in samples from people with type 1 
diabetes compared with samples from healthy donors (ESM Figure 2). In contrast, no 
significant differences were observed between groups for PPI, IA-2, IGRP or IAPP. A 
contingency analysis was also performed by aggregating qualitative calls (ESM Table 5). 
Samples with GAD multimer-positive populations (>0.05% of viable CD8+ T cells) were 
significantly enriched in the type 1 diabetes group (21/45 vs 8/50, p = Ϭ.ϬϬϭͿ. Saŵples with 
at least one detectable beta cell antigen-reactive CD8+ T cell population were also 
significantly enriched in the diabetes group (32/45 vs 20/50, p = Ϭ.ϬϬϮͿ. AĐĐordiŶglǇ, ďeta 
cell antigen reactivity within the peripheral CD8+ T cell compartment appears to be more 
common in individuals with type 1 diabetes relative to a healthy control group. 
 
 
DISCUSSION 
The importance of autoreactive CD8+ T cells is established in autoimmune diabetes. 
However, the availability of assays to enumerate beta cell antigen-specific CD8+ T cells 
remains limited. Here, we report the findings of a multi-centre study designed to test the 
reproducibility of a combinatorial HLA class I multimer assay for the detection and 
quantification of beta cell antigen-reactive CD8+ T cells in cryopreserved samples of 
PBMCs. From a logistical standpoint, the study was satisfactory. Acceptable post-thaw 
viability and sample recovery rates were observed across participating centres, and 
technically reproducible results were achieved for measurements of recall antigen-specific 
CD8+ T cells, which typically circulate in high numbers. These data concur with previous 
studies [14, 15, 23]. Similarly consistent results were achieved in a single-centre setting, 
where low %CVs across technical replicates were apparent not only for recall antigens, but 
also for beta cell antigens. Of note, the corresponding %CV values were approximately 
sixfold higher in multi-centre replicates, indicating greater technical variability. 
ANOVA suggested that systematic error or technical issues contributed to the observed 
differences between centres. The most notable disparities were apparent for 
measurements of PPI-specific CD8+ T cells in Denver. For logistical reasons, these samples 
were processed several months after the corresponding analyses in other centres. It is 
therefore possible that degradation of the PPI monomer over time contributed to 
increased levels of background staining. Alternatively, this site-specific difference could 
reflect a technical issue with the relevant combination of Qdots, linked to minor 
differences in cytometer configuration. This issue was not discernible for the spiked 
control sample, probably because of a stronger positive signal in that detection channel. 
Future studies may benefit from the incorporation of a non-spiked negative control or two 
partially spiked controls to screen for such technical issues. Significant differences in 
variance were also observed for insulin B-specific CD8+ T cell frequencies, suggesting a 
separate technical issue. However, it is difficult to establish whether the magnitude of this 
multimer-positive population was systematically underestimated in Seattle and Leiden or 
overestimated in Paris. 
Direct comparisons revealed that two beta cell antigen-specific CD8+ T cell populations 
occurred at higher frequencies in individuals with diabetes vs healthy donors. The most 
significant difference was observed for insulin B. This epitope is present in exogenous 
insulin, which is injected daily by individuals with type 1 diabetes. GAD-specific cells were 
also present in elevated numbers. Dasatinib may have affected the distinction between 
individuals with diabetes and healthy donors by enhancing detection of low-affinity T cells, 
thereby potentially increasing the level of staining observed in the absence of active 
disease. As some beta cell antigen-specific CD8+ T cell populations occurred at 
comparatively low frequencies that did not differ significantly between individuals with 
diabetes and healthy donors, further efforts to improve assay harmonisation through 
protocol standardisation may be worthwhile. In addition, pre-enrichment strategies may 
facilitate the detection of low-frequency beta cell antigen-reactive CD8+ T cells. However, 
further research is required to determine if the measurement of such low-frequency 
specificities is informative, especially across longitudinal series of samples. Comparing the 
prevalence of aggregated positive multimer stains, we detected GAD-specific CD8+ T cells 
more commonly in individuals with diabetes vs healthy donors, as reported previously 
using different assays [7, 24, 25, 26, 27]. Furthermore, across all beta cell epitopes, the 
prevalence of positive multimer stains was higher in individuals with diabetes vs healthy 
donors. These findings suggest that analysis of beta cell antigen-reactive CD8+ T cells for 
the purposes of disease classification would be most successful if multiple specif icities 
were measured in parallel. 
The disease specificity of the insulin B epitope was limited by the occurrence of positive 
results in some healthy donors. However, several of these control samples were only 
weakly positive, whereas a slightly higher number of samples from individuals with 
diabetes were more strongly positive. Assay specificity may therefore be improved further 
by increasing the positive threshold for this particular multimer. Indeed, future studies 
could benefit from setting unique thresholds for each beta cell epitope. As our staining 
panel did not include additional phenotypic markers, it was not possible to determine 
whether healthy individuals harbour unprimed naive T cells that recognise the insulin B 
epitope or whether the corresponding multimer displays a high level of background 
staining, possibly reflecting unexpected cross-reactivity with another specificity unrelated 
to the disease process. Although it is possible that dasatinib may obscure some 
differences between individuals with diabetes and healthy donors as a consequence of its 
enhancement of detection thresholds [20], a recent study has suggested otherwise [27]. 
Accordingly, future work may benefit from the incorporation of additional phenotypic 
markers and systematic evaluation of the effects of dasatinib. 
The goal of our study was to demonstrate that a complex HLA class I multimer assay could 
be implemented to provide technically reproducible results in multiple laboratories. 
Although our results are promising, assay reproducibility was higher in a single-centre 
setting. It may therefore be advisable to perform comparative evaluations in one 
laboratory, at least pending further standardisation of cytometry platforms, for example, 
via the introduction of photonic scales. Conceptually, multimer-based assays will be most 
informative for the evaluation of immune interventions designed to alter the frequencies 
of antigen-specific T cells, although further studies will be required to support the clinical 
relevance of such measurements. Such assays may also be well suited to investigate the 
phenomenon of epitope spreading, where different epitopes are recognised as a 
consequence of disease progression [28]. In this setting, combinatorial multimer assays may 
alloǁ the ideŶtifiĐatioŶ of ͚at-risk͛ iŶdiǀiduals aŶd faĐilitate the stratifiĐatioŶ of iŶdiǀiduals 
with established disease. The simultaneous evaluation of T cell phenotype, allowing 
inferences about memory status and functional attributes, may further enhance the utility 
of combinatorial multimer assays. In response to this suggestion, three of the groups that 
participated in this project are developing staining panels that include C-C motif 
chemokine receptor 7 (CCR7) and CD45RA to partition beta cell antigen-specific CD8+ T 
cells into naive, central memory, effector memory and terminally differentiated effector 
memory compartments. Other additions to the assay should be technically feasible, and 
downstream gene expression studies of multimer-positive T cells may provide further 
useful information [25, 29]. It will also be important to extend this approach to other HLA 
class I molecules that present disease-relevant epitopes. Indeed, published data have 
already shown that multimer-based assays can be used to detect beta cell antigen-specific 
CD8+ T cells restricted by HLA-A*01, HLA-A*03, HLA-A*11 and HLA-B*07 [30, 31, 32]. 
In conclusion, the present study supports the feasibility of monitoring beta cell antigen-
reactive CD8+ T cells using a combinatorial multimer staining approach. The assay was very 
effective in a single-centre setting, but showed greater variability across multi-centre 
replicates. Furthermore, the enumeration of beta cell antigen-specific CD8+ T cells 
revealed quantitative differences between individuals with diabetes and healthy donors. 
Collectively, these data highlight the potential utility and current limitations of 
combinatorial multimer staining in the context of type 1 diabetes. 
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HLA-A2 epitopes for combinatorial assay  
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Results and %CVs for single-centre replicates 
 
 
 
  
TABLE 3 
%CVs between centres for beta cell antigen multimer stains 
 
 
 
  
TABLE 4 
Centralised calls for individuals with diabetes and healthy donors 
 
 
 
 
Control, healthy donor; T1D, type 1 diabetes 
  
TABLE 5 
Single-centre calls for individuals with diabetes and healthy donors 
 
 
 
Control, healthy donor; T1D, type 1 diabetes 
  
FIGURE 1 
 
 
 
PBMC viability and recovery at each centre.  
 
(a) Post-thaw viability of sample set 1 at each centre, as measured by 
live/dead counting. Each symbol (circle, square, triangle, inverted 
triangle, diamond and hexagon) indicates a unique sample. The short 
horizontal lines show the mean values. Sample viability was significantly 
lower in Leiden than in Cardiff and Denver. (b) Post-thaw recovery of 
sample set 1 at each centre, estimated by comparing the live count with 
the total number of frozen cells. Symbols are identical to part (a). No 
significant differences were observed. (c) Post-thaw viability of sample 
set 2 at each centre. Each symbol indicates a unique sample. Sample 
viability was significantly lower in Denver than in other centres. (d) Post-
thaw recovery of sample set 2 at each centre. Symbols are identical to 
part (c). Sample recovery was significantly lower in Denver than in other 
centres. **p < 0.01 and ***p < 0.001 
  
FIGURE 2 
 
 
 
 
Multimer analysis for recall antigens. (a) Dot plots show representative data 
for sample 1 of sample set 1, stained in Leiden using the CMV, non-interfacing 
(Neg), EBV and influenza M1 (Flu) multimers. Each subpart depicts staining of 
live CD8+ T cells by the Qdot pair of interest after combinatorial gating. For 
this sample, positive double staining was virtually absent for the CMV and 
control multimers, but a clear signal was detected with the EBV and influenza 
multimers. (b) Multi-centre CMV staining results. The %CV was 20 for sample 
3. Remaining samples were negative. (c) Multi-centre EBV staining results. The 
%CV values were 42 for sample 1 and 48 for sample 4. Remaining samples 
were negative. (d) Multi-centre influenza staining results. The %CV values 
were 23 for sample 1, 45 for sample 2 and 25 for sample 3. Remaining 
samples were negative. Each y-axis indicates the observed percentage of live 
CD8+ T cells labelled with the corresponding Qdot pair after combinatorial 
gating. Symbols indicate different centres. No significant differences were 
observed across centres. Circles, Cardiff; squares, Leiden; triangles, Paris; 
inverted triangles, Seattle; hexagons, Denver 
 
FIGURE 3 
 
 
 
Multimer analysis for beta cell antigens.  
(a) Dot plots show representative data for the clone-spiked sample, stained using beta cell antigen 
multimers and a pool of recall antigen multimers in Leiden. Each subpart depicts staining of live 
CD8+ T cells by the Qdot pair of interest after combinatorial gating. The sample was spiked with CMV- 
and PPI-specific CD8+ T cell clones. A clear signal was detected for each clone.   (b) Dot plots show 
representative data for sample 16 (individual 338), stained using beta cell antigen multimers and a 
pool of recall antigen multimers in Leiden. Each subpart depicts staining for Qdot pairs as in part  (a). 
Strong positive staining was observed with the recall antigen multimers, moderate positive staining 
was observed with the insulin B multimer and weak staining was observed with the GAD multimer.  
(c) Multimer staining results for the clone-spiked sample in each centre. The line indicates the mean 
value observed across all five centres. The %CV values were 20 for the non-interfacing multimer, 34 
for the pool of recall antigen multimers, 47 for the insulin B multimer, 43 for the PPI multimer, 76 for 
the GAD multimer, 65 for the IA-2 multimer, 89 for the IGRP multimer and 68 for the IAPP multimer. 
Circles, Cardiff; squares, Leiden; triangles, Paris; inverted triangles, Seattle; hexagons, Denver. Flu, 
influenza M1; Ins B, insulin B; Neg, non-interfacing 
  
FIGURE 4 
 
 
 
 
Multimer staining results for each individual sample across all participating 
centres. Each figure part depicts the percentage of live CD8+ T cells positive for 
the Qdot pair corresponding to (a) the non-interfacing control multimer, (b) the 
pool of recall antigen multimers, (c) the insulin B multimer, (d) the PPI 
multimer, (e) the GAD multimer, (f) the IA-2 multimer, (g) the IGRP multimer 
and (h) the IAPP multimer after combinatorial gating. In each graph, symbols 
indicate the corresponding % observed at each centre for samples 1–10 
(healthy donors) and 11–19 (individuals with type 1 diabetes). Circles, Cardiff; 
squares, Leiden; triangles, Paris; inverted triangles, Seattle; hexagons, Denver 
 
 
  
FIGURE 5 
 
 
 
 
Beta cell antigen multimer staining results with no significant differences 
between centres. Although staining levels differed substantially for different 
individuals, no significant differences were observed in the magnitude of 
staining with (a) the non-interfacing control multimer, (b) pooled CMV, EBV 
and influenza multimers, (c) the GAD multimer, (d) the IA-2 multimer, (e) the 
IGRP multimer or (f) the IAPP multimer. In each figure part, each symbol 
indicates the staining observed for a single individual (numbered as in ESM 
Table 3). Healthy donors (1–10) and individuals with type 1 diabetes (11–20) 
are designated consecutively in blue and red symbols, respectively, as follows: 
circle, square, upward triangle, downward triangle, diamond, half-filled circle, 
half-filled square, half-filled upward triangle, half-filled downward triangle 
and half-filled diamond 
 
 
 
  
FIGURE 6 
 
 
 
Beta cell antigen multimer staining results with significant differences between 
centres. (a) The magnitude of insulin B multimer staining was significantly 
lower in Leiden and Seattle than in Paris. (b) The magnitude of PPI multimer 
staining was significantly higher in Denver than in Cardiff, Leiden, Paris and 
Seattle. In each part, each symbol indicates the staining observed for a single 
individual, with the same colours and symbol designations as in Fig. 5. In all 
figure parts, * p < 0.05 
 
 
 
